ClearPoint Neuro, Inc.CLPTEarnings & Financial Report
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
CLPT Q4 FY2025 Key Financial Metrics
Revenue
$10.4M
Gross Profit
$6.4M
Operating Profit
$-7.0M
Net Profit
N/A
Gross Margin
61.5%
Operating Margin
-67.7%
Net Margin
N/A
YoY Growth
34.0%
EPS
$-0.26
ClearPoint Neuro, Inc. Q4 FY2025 Financial Summary
ClearPoint Neuro, Inc. reported revenue of $10.4M (up 34.0% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $4.0M, operating expenses totaled $13.4M.
Key Financial Metrics
| Total Revenue | $10.4M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 61.5% |
| Operating Margin | -67.7% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
ClearPoint Neuro, Inc. Q4 FY2025 revenue of $10.4M breaks down across 4 segments, led by Neurosurgery Navigation And Therapy Disposable Products at $4.7M (45.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45.1% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27.0% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23.0% |
| Other | $502.0K | 4.8% |
ClearPoint Neuro, Inc. Revenue by Segment — Quarterly Trend
ClearPoint Neuro, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Neurosurgery Navigation And Therapy Disposable Products and Biologics And Drug Delivery Services And License Fees) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | $3.4M | $3.4M | $3.3M |
| Biologics And Drug Delivery Services And License Fees | $2.8M | — | — | — |
| Biologics And Drug Delivery Disposable Products | $2.4M | — | — | — |
| Other | $502.0K | — | — | $517.0K |
ClearPoint Neuro, Inc. Annual Revenue by Year
ClearPoint Neuro, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $37.0M).
ClearPoint Neuro, Inc. Quarterly Revenue & Net Profit History
ClearPoint Neuro, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $10.4M | +34.0% | N/A | N/A |
| Q3 FY2025 | $8.9M | +9.1% | $-5.9M | -66.5% |
| Q2 FY2025 | $9.2M | +17.3% | $-5.8M | -63.3% |
| Q1 FY2025 | $8.5M | +11.1% | $-6.0M | -71.0% |
| Q4 FY2024 | $7.8M | +14.1% | N/A | N/A |
| Q3 FY2024 | $8.1M | +41.0% | $-5.0M | -61.2% |
| Q2 FY2024 | $7.9M | +32.1% | $-4.4M | -56.1% |
| Q1 FY2024 | $7.6M | +40.6% | $-4.1M | -54.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.6M | $7.9M | $8.1M | $7.8M | $8.5M | $9.2M | $8.9M | $10.4M |
| YoY Growth | 40.6% | 32.1% | 41.0% | 14.1% | 11.1% | 17.3% | 9.1% | 34.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $53.6M | $52.6M | $40.2M | $39.2M | $30.1M | $62.9M | $60.4M | $97.7M |
| Liabilities | $19.1M | $20.4M | $11.2M | $13.8M | $10.1M | $43.1M | $44.5M | $69.7M |
| Equity | $34.6M | $32.1M | $29.0M | $25.4M | $20.0M | $19.7M | $15.9M | $28.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.8M | $-2.7M | $-1.2M | $-1.2M | $-6.2M | $-2.6M | $-3.1M | $-12.1M |